Nita A Limdi1, Todd M Brown, Aditi Shendre, Nianjun Liu, Charles E Hill, Timothy M Beasley. 1. aDepartment of Neurology bDepartment of Medicine, Division of Cardiovascular Diseases cDepartment of Epidemiology dDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA eDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA.
Abstract
OBJECTIVE: We evaluated whether percent time in target range (PTTR), risk of over-anticoagulation [international normalized ratio (INR)>4], and risk of hemorrhage differ by race. As PTTR is a strong predictor of hemorrhage risk, we also determined the influence of PTTR on the risk of hemorrhage by race. PARTICIPANTS AND METHODS: Among 1326 warfarin users, PTTR was calculated as the percentage of interpolated INR values within the target range of 2.0-3.0. PTTR was also categorized as poor (PTTR<60%), good (60≤PTTR<70%), or excellent (PTTR≥70%) anticoagulation control. Over-anticoagulation was defined as INR more than 4 and major hemorrhages included serious, life-threatening, and fatal bleeding episodes. Logistic regression and survival analyses were carried out to evaluate the association of race with PTTR (≥60 vs. <60) and major hemorrhages, respectively. RESULTS: Compared with African Americans, European Americans had higher PTTR (57.6 vs. 49.1%; P<0.0001) and were more likely to attain 60≤PTTR<70% (22.9 vs. 13.1%; P<0.001) or PTTR of at least 70% (26.9 vs. 18.2%; P=0.001). Older (>65 years) patients without venous thromboembolism indication and chronic kidney disease were more likely to attain PTTR of at least 60%. After accounting for clinical and genetic factors, and PTTR, African Americans had a higher risk of hemorrhage [hazard ratio (HR)=1.58; 95% confidence interval (CI): 1.04-2.41; P=0.034]. Patients with 60≤PTTR<70% (HR=0.62; 95% CI: 0.38-1.02; P=0.058) and PTTR of at least 70% (HR=0.27; 95% CI: 0.15-0.49; P<0.001) had a lower risk of hemorrhage compared with those with PTTR less than 60%. CONCLUSION: Despite the provision of warfarin management through anticoagulation clinics, African Americans achieve a lower overall PTTR and have a significantly higher risk of hemorrhage. Personalized medicine interventions tailored to African American warfarin users need to be developed.
OBJECTIVE: We evaluated whether percent time in target range (PTTR), risk of over-anticoagulation [international normalized ratio (INR)>4], and risk of hemorrhage differ by race. As PTTR is a strong predictor of hemorrhage risk, we also determined the influence of PTTR on the risk of hemorrhage by race. PARTICIPANTS AND METHODS: Among 1326 warfarin users, PTTR was calculated as the percentage of interpolated INR values within the target range of 2.0-3.0. PTTR was also categorized as poor (PTTR<60%), good (60≤PTTR<70%), or excellent (PTTR≥70%) anticoagulation control. Over-anticoagulation was defined as INR more than 4 and major hemorrhages included serious, life-threatening, and fatal bleeding episodes. Logistic regression and survival analyses were carried out to evaluate the association of race with PTTR (≥60 vs. <60) and major hemorrhages, respectively. RESULTS: Compared with African Americans, European Americans had higher PTTR (57.6 vs. 49.1%; P<0.0001) and were more likely to attain 60≤PTTR<70% (22.9 vs. 13.1%; P<0.001) or PTTR of at least 70% (26.9 vs. 18.2%; P=0.001). Older (>65 years) patients without venous thromboembolism indication and chronic kidney disease were more likely to attain PTTR of at least 60%. After accounting for clinical and genetic factors, and PTTR, African Americans had a higher risk of hemorrhage [hazard ratio (HR)=1.58; 95% confidence interval (CI): 1.04-2.41; P=0.034]. Patients with 60≤PTTR<70% (HR=0.62; 95% CI: 0.38-1.02; P=0.058) and PTTR of at least 70% (HR=0.27; 95% CI: 0.15-0.49; P<0.001) had a lower risk of hemorrhage compared with those with PTTR less than 60%. CONCLUSION: Despite the provision of warfarin management through anticoagulation clinics, African Americans achieve a lower overall PTTR and have a significantly higher risk of hemorrhage. Personalized medicine interventions tailored to African American warfarin users need to be developed.
Authors: Julie C Lauffenburger; Joel F Farley; Anil K Gehi; Denise H Rhoney; M Alan Brookhart; Gang Fang Journal: Am J Cardiol Date: 2015-02-02 Impact factor: 2.778
Authors: Harriette G C Van Spall; Lars Wallentin; Salim Yusuf; John W Eikelboom; Robby Nieuwlaat; Sean Yang; Conrad Kabali; Paul A Reilly; Michael D Ezekowitz; Stuart J Connolly Journal: Circulation Date: 2012-10-01 Impact factor: 29.690
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Sean D Pokorney; DaJuanicia N Simon; Laine Thomas; Gregg C Fonarow; Peter R Kowey; Paul Chang; Daniel E Singer; Jack Ansell; Rosalia G Blanco; Bernard Gersh; Kenneth W Mahaffey; Elaine M Hylek; Alan S Go; Jonathan P Piccini; Eric D Peterson Journal: Am Heart J Date: 2015-04-01 Impact factor: 4.749
Authors: Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Salina P Waddy; Allen J Solomon; Adan Z Becerra; Julia B Ward; Kevin E Chan; Chyng-Wen Fwu; Jenna M Norton; Paul W Eggers; Kevin C Abbott; Paul L Kimmel Journal: J Am Soc Nephrol Date: 2020-02-20 Impact factor: 10.121
Authors: Minami Ohara; Yasuhiko Suzuki; Saki Shinohara; Inna Y Gong; Crystal L Schmerk; Rommel G Tirona; Ute I Schwarz; Ming-Shien Wen; Ming Ta Michael Lee; Kiyoshi Mihara; Edith A Nutescu; Minoli A Perera; Larisa H Cavallari; Richard B Kim; Harumi Takahashi Journal: Clin Pharmacokinet Date: 2019-08 Impact factor: 6.447
Authors: Tian Ge; Marguerite R Irvin; Amit Patki; Vinodh Srinivasasainagendra; Yen-Feng Lin; Hemant K Tiwari; Nicole D Armstrong; Barbara Benoit; Chia-Yen Chen; Karmel W Choi; James J Cimino; Brittney H Davis; Ozan Dikilitas; Bethany Etheridge; Yen-Chen Anne Feng; Vivian Gainer; Hailiang Huang; Gail P Jarvik; Christopher Kachulis; Eimear E Kenny; Atlas Khan; Krzysztof Kiryluk; Leah Kottyan; Iftikhar J Kullo; Christoph Lange; Niall Lennon; Aaron Leong; Edyta Malolepsza; Ayme D Miles; Shawn Murphy; Bahram Namjou; Renuka Narayan; Mark J O'Connor; Jennifer A Pacheco; Emma Perez; Laura J Rasmussen-Torvik; Elisabeth A Rosenthal; Daniel Schaid; Maria Stamou; Miriam S Udler; Wei-Qi Wei; Scott T Weiss; Maggie C Y Ng; Jordan W Smoller; Matthew S Lebo; James B Meigs; Nita A Limdi; Elizabeth W Karlson Journal: Genome Med Date: 2022-06-29 Impact factor: 15.266
Authors: Tanima De; Cristina Alarcon; Wenndy Hernandez; Ina Liko; Larisa H Cavallari; Julio D Duarte; Minoli A Perera Journal: JAMA Date: 2018-10-23 Impact factor: 56.272
Authors: Innocent G Asiimwe; Eunice J Zhang; Rostam Osanlou; Amanda Krause; Chrisly Dillon; Guilherme Suarez-Kurtz; Honghong Zhang; Jamila A Perini; Jessicca Y Renta; Jorge Duconge; Larisa H Cavallari; Leiliane R Marcatto; Mark T Beasly; Minoli A Perera; Nita A Limdi; Paulo C J L Santos; Stephen E Kimmel; Steven A Lubitz; Stuart A Scott; Vivian K Kawai; Andrea L Jorgensen; Munir Pirmohamed Journal: Clin Pharmacol Ther Date: 2020-01-28 Impact factor: 6.875
Authors: Eman Nawash Alhmoud; Hazem Elewa; Mohammed S Abdul Gelil; Osama B Abd El Samad; Abdelnasser Y Elzouki Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389